Chinese Tech Stocks in Focus: WuXi Biologics & Kingdee

WuXi Biologics (2269-hk) & Kingdee (268-hk), the two Chinese tech stocks, have shown promising bullish signals...

Uptrend 2

WuXi Biologics (2269.hk): Consolidate before Next Rally


WuXi Biologics (2269.hk), a biopharmaceutical group, released a positive profit alert on July 29, stating that 1H net income is expected to increase by more than 58% on year. The company said "more client projects were added into the Group's pipeline expediting the development and manufacturing of potential treatments related to COVID-19 in support of its global clients". 

As shown on the daily chart, WuXi Biologics' share price has finished a measured move after reaching a high at $193.0 on August 6, suggesting a potential consolidation before the next rally. Bullish investors might consider $152.2 as the nearest support, which is the 61.8% Fibonacci retracement of the rally started from March. The 1st and 2nd resistances are expected to be located at $193.0 and $222.0 respectively. Alternatively, a break below $152.2 may open a path to the next support at $139.7.

Source: TradingView, Gain Capital


Kingdee (268.hk): Strong Bullish Momentum


Kingdee (268.hk), a software company, issued a profit warning in early July, pointing out that it expects to record a 1H net loss of 200 - 300 million yuan compared with a net profit of 110 million yuan last year. However, its share price showed resilience as investor continue to chase technology stocks.


Kingdee's rally, after breaking above a 2-year consolidation range, remains solid. For the stock to keep its strong bullish momentum, the level at $19.70 is expected to act as the nearest support. The 1st and 2nd resistances are expected to be located at $25.30 and $27.00. Alternatively, losing $19.70 might suggest a deeper price correction to $17.00.

Source: TradingView, Gain Capital




More from Stocks

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.